This site is intended for Healthcare professionals only.

Lupin gets USFDA nod to market its skin conditions cream


Lupin gets USFDA nod to market its skin conditions cream

New Delhi: Drug firm Lupin said it has received the final nod from the US health regulator to market its Clobetasol Propionate cream used for the treatment of various skin conditions.

The company has received final approval to market its generic Clobetasol Propionate cream USP, 0.05 percent, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.

The company’s product is a generic version of Fougera Pharmaceuticals Inc’s Temovate cream, it added.

The cream “is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,” it added.



Source: PTI
0 comment(s) on Lupin gets USFDA nod to market its skin conditions cream

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted